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Background
Limited direct comparative data exist between the recom-
mended dual NRTI fixed dose combinations, tenofovir/
emtricitabine (Truvada) and abacavir/lamivudine
(Kivexa). A recent study (HEAT) evaluated these dual
NRTI backbones with a boosted PI. However, there are no
data comparing these two formulations when used with
other antiretroviral drugs.
Methods
Retrospective study of HIV-1 infected patients in two Gen-
ito-Urinary Medicine clinics. Patients taking either Tru-
vada or Kivexa were included. Data including previous
treatment, resistance test, HLA B5701 status, pre-treat-
ment CD4 count, plasma viral load, age, ethnicity, renal
function, lipid profiles were gathered. Primary endpoint
was the proportion of subjects with viral load <50 copies/
ml at 48 weeks.
Summary of results
232 patients were included, of which 129 were on Tru-
vada and 103 on Kivexa; 114 were treatment naive.
(Tables 1 and 2.)
Conclusion
Truvada was non-inferior to Kivexa in this cohort. How-
ever, virological failure was observed in three patients
when Kivexa was used with an NNRTI. Median CD4
increase was greater in Truvada arm at 48 weeks but this
was not statistically significant. Further data will be pre-
sented at the meeting.
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Table 1: 
Truvada Kivexa p-value
Total number 129 103
Male 119 (92.3%) 96 (93.2%) 0.78
Female 10 7
Age (median, IQR) 38 (32.43) 38 (32.43)
Ethnicity
African 28 (21.7%) 39 (37.9%) 0.001
Causcasian 95 (73.6%) 55 (50.5%) 0.001
Other 6 (4.7%) 12 (11.6%) 0.001
Smoker 51 (42.5%) 31 (30.4%) 0.06
History of cardiovascular event 5 (3.9%) 4 (3.9%) 0.63
Hypertensive 9 (7.0%) 13 (12.6%) 0.14
Diabetic 3 (2.3%) 6 (5.8%) 0.14
HBV co-infected 13 (10.1%) 1 (1.0%) 0.02
HCV co-infected 1 (0.8%) 4 (3.9%) 0.27
AIDS diagnosis 26 (20.2%) 19 (18.5%) 0.74
ART experienced 63 (48.8%) 53 (51.5%) 0.74
Current drug
PI 32 (24.8%) 19 (18.5%) 0.25
NNRTI 97 (75.2%) 84 (81.6%)
Baseline laboratory markers
CD4 (cells/mm3) median 235 228 0.49
Viral load (log copies/ml) median 4.5 3.8 0.07
Cholesterol (mmol/l) median 4.3 4.5 0.05
HDL (mmol/l) median 1.1 1.2 0.52
Triglyceride (mmol/l) median 1.4 1.3 0.59
GFR 110 107 0.14
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Table 2: Week 48 results (ITT-E, Missing = excluded).
ARV experienced ARV experienced ARV experienced ARV naive ARV naive ARV naive
Truvada (n = 60) Kivexa (n = 53) p-value Truvada (n = 64) Kivexa (n = 50) p-value
Viral load <50 copies/ml 47/49 (95.9%) 35/36 (97.2%) 1.00 56/59 (94.9%) 29/33 (87.9%) 0.22
Median CD4 increase (cells/mm3) 83 62 0.36 208 170 0.59
Withdrawn due to adverse events 1 0 0 0
Suspected ABC HSR 0 0 0 1
Proximal renal tubular dysfunction 0 0 0 0
Virological failure 0 1 0 2
